Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Lufax Plans Hong Kong listing

-Bloomberg https://www.bloomberg.com/news/articles/2022-08-15/fintech-giant-lufax-plans-hong-kong-listing-to-hedge-us-risk?utm_campaign=socialflow-organic&utm_source=twitter&utm_medium=social&utm_content=business&cmpid=socialflow-twitter-business
byCharles Gross
August 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Bloomberg

https://www.bloomberg.com/news/articles/2022-08-15/fintech-giant-lufax-plans-hong-kong-listing-to-hedge-us-risk?utm_campaign=socialflow-organic&utm_source=twitter&utm_medium=social&utm_content=business&cmpid=socialflow-twitter-business

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AbbVie Earlier Announced European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease

By Charles Gross
November 23, 6:48 AM
AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had in

ABBV